Retina

Timothy Lai, MD, shares promising one-year results from the SALWEEN study on faricimab for polypoidal choroidal vasculopathy at EURETINA 2025.

In both trials, Beacon’s lead program, laru-zova, was found to be well-tolerated by SKYLINE participants through month 36 and DAWN patients at month 9 or longer.

Roche reveals promising results for Vabysmo in treating eye diseases, showcasing significant vision improvements and safety in recent clinical trials.

OCT-A angiography can help reveal early neurodegenerative disease signs, offering a non-invasive method for identifying high-risk patients through retinal analysis.

Roche's Contivue platform gains EU CE mark, offering innovative treatment for neovascular AMD with fewer injections and promising long-term vision outcomes.

A study reveals similar risks of sight-threatening diabetic retinopathy in pregnant women with type 1 diabetes compared to nonpregnant controls.

Neurotech Pharmaceuticals enhances its leadership by appointing Peter J. McDonnell, MD, a leading ophthalmology expert, to its Board of Directors.

MCO-010 receives Orphan and RMAT designations, highlighting its potential as a groundbreaking therapy for various retinal dystrophies.

Discover how dropless vitrectomy with suprachoroidal injection effectively controls inflammation, offering a promising alternative to traditional eye drop therapy.

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration

Included is the supplemental Biologics License Application (sBLA) for EYLEA HD seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications.

Annexin Pharmaceuticals initiates a Phase 2a study for ANXV in diabetic retinopathy to explore new treatment options and improve patient outcomes.

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and, in some cases, blindness.

jCyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

The two aim to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases.

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

A complex case of uveitis linked to syphilis highlights the need for thorough history-taking and multidisciplinary management in diagnosis and treatment.

Advanced imaging and awareness of systemic risk factors are essential.

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated in subjects with non-proliferative diabetic retinopathy

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia under the terms of the agreement.

Neurotech Pharmaceuticals announced the first commercial manufacturing, shipment, and surgical procedure of ENCELTO, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2.